Company intelligence / Profile preview
CARsgen Therapeutics
- Ownership
- Public · 2171.HK
- Employees
- ~500
- Development stage
- Commercial
Overview
CARsgen has achieved significant clinical milestones:
- Zevor-cel approved by NMPA in China.
- Satri-cel (CT041) completed confirmatory Phase II trial enrollment in China with positive topline results for advanced gastric/gastroesophageal junction cancers after at least two prior lines of therapy.
- Multiple adjuvant studies and early-phase trials underway for both hematologic malignancies and solid tumors.
- Active development of allogeneic pipeline products.
- Therapeutic areas
- OncologyImmunology
- Modalities
- CAR T-cell therapies (autologous and allogeneic)cell therapy
- Industry
- Biotech
Drug pipeline
54 assets53 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on CARsgen Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CARsgen Therapeutics.